Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases.

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

Of course being diagnosed with metastatic non-small cell lung cancer (NSCLC) feels overwhelming. Between juggling treatments, managing symptoms and side effects, and dealing with the anxiety of a ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...